FSD Pharma Inc appoints Adnan Bashir as independent director of the company

Bashir, former Managing Director of Al Batha Group, a Dubai-based business conglomerate, has over 14 years of experience in strategic management and operations.

FSD Pharma Inc (NASDAQ:HUGE) (CSE:HUGE) (FRA:0K9) announced that it has appointed Adnan Bashir as an independent member of the company’s Board of Directors.

Bashir, former Managing Director of Al Batha Group, a Dubai-based business conglomerate, has over 14 years of experience in strategic management and operations.

“Adnan’s wealth of experience will add significant value to our board. We look forward to working with him to restore FSD,” FSD Pharma Co-Chairman Anthony Durkacz said in a statement.

READ: FSD Pharma invests resources behind ancient anti-inflammatory drug as potential coronavirus therapy

The company said Bashir was appointed to fill the vacancy on the board following the resignation of Frank Lavelle.

FSD Pharma’s Board of Directors now consists of Anthony Durkacz, Zeeshan Saeed, Nitin Kaushal, Lawrence (Larry) Latowsky, Fernando Cugliari, Donal Carroll and Adnan Bashir.

FSD Pharma is a publicly traded holding company with subsidiary FSD Pharma BioSciences Inc, a biotechnology-based pharmaceutical R&D company focused on the development of multiple applications of its lead anti-inflammatory drug FSD-201.

The drug is now one of many advanced therapies that could help reduce serious and deadly lung infections in coronavirus (COVID-19) patients.

Contact Sean at [email protected]